OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC restated a buy rating and issued a $4.25 price objective on shares of OncoCyte in a report on Friday, August […]
13 Oct 07:25 · The Markets Daily